» Articles » PMID: 37751451

Investigation of Evolutionary Dynamics for Drug Resistance in 3D Spheroid Model System Using Cellular Barcoding Technology

Overview
Journal PLoS One
Date 2023 Sep 26
PMID 37751451
Authors
Affiliations
Soon will be listed here.
Abstract

Complex evolutionary dynamics governing the drug resistance is one of the major challenges in cancer treatment. Understanding these mechanisms requires a sequencing technology with higher resolution to delineate whether pre-existing or de novo drug mechanisms are behind the drug resistance. Combining this technology with clinically very relevant model system, namely 3D spheroids, better mimicking tumorigenesis and drug resistance have so far been lacking. Thus, we sought to establish dabrafenib and irinotecan resistant derivatives of barcoded 3D spheroids with the ultimate aim to quantify the selection-induced clonal dynamics and identify the genomic determinants in this model system. We found that dabrafenib and irinotecan induced drug resistance in 3D-HT-29 and 3D-HCT-116 spheroids are mediated by pre-existing and de novo resistant barcodes, indicating the presence of polyclonal drug resistance in this system. Moreover, whole-exome sequencing analysis found chromosomal gains and mutations associated with dabrafenib and irinotecan resistance in 3D-HT-29 and 3D-HCT-116 spheroids. Last, we show that dabrafenib and irinotecan resistance are also mediated by multiple drug resistance by detection of upregulation of the drug efflux pumps, ABCB1 and ABCG2, in our spheroid model system. Overall, we present the quantification of drug resistance and evolutionary dynamics in spheroids for the first time using cellular barcoding technology and the underlying genomic determinants of the drug resistance in our model system.

Citing Articles

Generation of Porcine and Rainbow Trout 3D Intestinal Models and Their Use to Investigate Astaxanthin Effects In Vitro.

Arcuri S, Pennarossa G, Pasquariello R, Prasadani M, Gandolfi F, Brevini T Int J Mol Sci. 2024; 25(11).

PMID: 38892151 PMC: 11172962. DOI: 10.3390/ijms25115966.


Optimizing cancer therapy: a review of the multifaceted effects of metronomic chemotherapy.

Basar O, Mohammed S, Qoronfleh M, Acar A Front Cell Dev Biol. 2024; 12:1369597.

PMID: 38813084 PMC: 11133583. DOI: 10.3389/fcell.2024.1369597.

References
1.
Hu S, Aitken M, Epstein A, Trusheim M, Berndt E . Market watch: defining and quantifying the use of personalized medicines. Nat Rev Drug Discov. 2013; 12(12):896-7. DOI: 10.1038/nrd4177. View

2.
Muriithi W, Wanjiku Macharia L, Pilotto Heming C, Echevarria J, Nyachieo A, Niemeyer Filho P . ABC transporters and the hallmarks of cancer: roles in cancer aggressiveness beyond multidrug resistance. Cancer Biol Med. 2020; 17(2):253-269. PMC: 7309456. DOI: 10.20892/j.issn.2095-3941.2019.0284. View

3.
Mittapalli R, Vaidhyanathan S, Dudek A, Elmquist W . Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther. 2012; 344(3):655-64. PMC: 3583506. DOI: 10.1124/jpet.112.201475. View

4.
Ramirez M, Rajaram S, Steininger R, Osipchuk D, Roth M, Morinishi L . Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat Commun. 2016; 7:10690. PMC: 4762880. DOI: 10.1038/ncomms10690. View

5.
Sun G, Yang L, Dong C, Ma B, Shan M, Ma B . PRKDC regulates chemosensitivity and is a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients. Oncol Rep. 2017; 37(6):3536-3542. DOI: 10.3892/or.2017.5634. View